Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research.
Roger S McIntyre, Angela T H Kwan, Rodrigo B Mansur, Albino J Oliveira-Maia, Kayla M Teopiz, Vladimir Maletic, Trisha Suppes, Stephen M Stahl, Joshua D Rosenblat
The American journal of psychiatry January 1, 2025 DOI: 10.1176/appi.ajp.20230902 via PubMed
Summary
AI-generated from the abstractPsychedelics show promise for treating difficult-to-treat psychiatric disorders like major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder, with preliminary evidence also supporting efficacy in tobacco and alcohol use disorders. However, concerns exist about the interpretability and translatability of study results due to insufficiently characterized short- and long-term safety, abuse liability, and the essentiality of the psychedelic experience and psychological support. This overview reviews methodological aspects affecting inferences and interpretation of extant psychedelic studies and provides guidance for future research and development critical to study interpretation and clinical implementation.
Study at a glance
| Characteristics | Overview Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Depressive disorders Methodology Psychedelics |
| Citations | 23 |
| Key finding | Methodological aspects affecting inferences and interpretation of psychedelic studies in psychiatric disorders are reviewed, and guidance for future research and development is provided. |
Abstract
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary evidence also supports efficacy in other psychiatric disorders (e.g., tobacco and alcohol use disorders). Notwithstanding the interest and promise of psychedelics, concerns have arisen with respect to the interpretability and translatability of study results. For example, aspects related to short- and long-term safety, abuse liability, and the essentiality of the psychedelic "trip" and psychological support are, inter alia, insufficiently characterized with psychedelic agents. The overarching aims in this overview are 1) to review methodological aspects that affect inferences and interpretation of extant psychedelic studies in psychiatric disorders, and 2) to provide guidance for future research and development of psychedelic treatment in psychiatry, critical to study interpretation and clinical implementation.